# Eran Perry

> Eran Perry is a convertible note investor at Upstream Bio backing Wellness and Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Upstream Bio](https://shizune.co/investors/profile/upstream-bio)
- Total investments: 1
- Last investment: Feb 2021
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/eran-perry-a436405/details/experience

Eran Perry is a convertible note investor at Upstream Bio focused on Wellness and Health Care. Eran Perry is the Co-Founder & Managing Director of MII. He previously worked at Musli Thyropeutics as a Board Member. Eran Perry attended Columbia Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Wellness | 1 | 100% |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MyBiotics Pharma LTD | MyBiotics innovative technologies; MyCrobeTM and SuperDonorTM allow us to be in the front of the microbiome field. Both technologies resolve the three critical factors in the probiotic development market. Delivery, Targeting and Colonization. MyCrobeTM and SuperDonorTM provide single or multi-bacterial combinations for targeted treatment, wholemicrobiome restoration and the first actual screening method to replace FMT microbiome transplantations. MyBiotics focus is to return the bacterial population to its healthy and balanced state by using live bacteria that will colonize and compete with the existent disease-promoting population. | $3.5M | Convertible Note | Feb 03, 2021 |  |

1 of 1 investments shown.

## About Upstream Bio

VC Fund · Waltham, United States

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses.

5 contacts available at Upstream Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Aaron Deykin | Chief Medical Officer and Head of Research and Development | https://shizune.co/investors/profile/aaron-deykin-f532 |
| Adam Houghton | Chief Business Officer | https://shizune.co/investors/profile/adam-houghton-28f8 |
| Eran Perry | Co-Founder and Board Member | https://shizune.co/investors/profile/eran-perry |
| Lisa Fiering | SVP, People and Culture | https://shizune.co/investors/profile/lisa-fiering-6c88 |
| Michael Gray | Chief Financial Officer and Chief Operating Officer | https://shizune.co/investors/profile/michael-gray-1ad6 |

## Similar investors

### Similar stage
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund

## FAQ

### What does Eran Perry invest in?

Eran Perry invests primarily in Wellness, Health Care and Biotechnology startups, most often at Convertible Note stage. Most of the 1 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eran Perry last invest?

The most recent investment recorded for Eran Perry closed in Feb 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co